

**PD Dr. Martin Früh**

Kantonsspital St.Gallen  
ONKO  
Switzerland

## publications

as of: 15.02.2018

### journal paper/review

Parra-Guillen Z P, Berger P B, Haschke M, Donzelli M, Winogradova D, Pfister B, Früh M, Gillessen Sommer S, Krähenbühl S, Kloft C, Joerger M. Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non-small-Cell Lung Cancer Receiving Erlotinib Treatment. *Basic Clin Pharmacol Toxicol* 2017; 121:309-315.

Rosell R, Dafni U, Felip E, Curioni-Fontecedro A, Gautschi O, Peters S, Massutí B, Palmero R, Aix S P, Carcereny E, Früh M, Pless M, Popat S, Kotsakis A, Cuffe S, Bidoli P, Favaretto A, Froesch P, Reguart N, Puente J, Coate L, Barlesi F, Rauch D, Thomas M, Camps C, Gómez-Codina J, Majem M, Porta R, Shah R, Hanrahan E, Kammler R, Ruepp B, Rabaglio M, Kassapian M, Karachaliou N, Tam R, Shames D S, Molina-Vila M A, Stahel R A, BELIEF collaborative group . Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. *Lancet Respir Med* 2017; 5:435-444.

Peters S, Gettinger S, Johnson M L, Jänne P A, Garassino M C, Christoph D, Toh C K, Rizvi N A, Chaft J E, Carcereny Costa E, Patel J D, Chow L Q M, Koczywas M, Ho C, Früh M, van den Heuvel M, Rothenstein J, Reck M, Paz-Ares L, Shepherd F A, Kurata T, Li Z, Qiu J, Kowanz M, Mocchi S, Shankar G, Sandler A, Felip E. Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH). *J Clin Oncol* 2017; 35:2781-2789.

Baty F, Joerger M, Früh M, Klingbiel D, Zappa F, Brutsche M. 24h-gene variation effect of combined bevacizumab/erlotinib in advanced non-squamous non-small cell lung cancer using exon array blood profiling. *J Transl Med* 2017; 15:66.

Gautschi O, Milia J, Filleron T, Wolf J, Carbone D P, Owen D, Camidge R, Narayanan V, Doebele R C, Besse B, Remon-Masip J, Jänne P A, Awad M M, Peled N, Byoung C C, Karp D D, Van Den Heuvel M, Wakelee H A, Neal J W, Mok T S K, Yang J C H, Ou S H I, Pall G, Froesch P, Zalcman G, Gandara D R, Riess J W, Velcheti V, Zeidler K, Diebold J, Früh M, Michels S, Monnet I, Popat S, Rosell R, Karachaliou N, Rothschild S I, Shih J Y, Warth A, Muley T, Cabillic F, Mazières J, Drilon A. Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry. *J Clin Oncol* 2017; 35:1403-1410.

Glatzer M, Rittmeyer A, Müller J, Opitz I, Papachristofilou A, Psallidas I, Früh M, Born D, Putora P M. Treatment of limited disease small cell lung cancer: the multidisciplinary team. *Eur Respir J* 2017; 50:.

- Glatzer M, Rittmeyer A, Müller J, Opitz I, Früh M, Papachristofilou A, Psallidas I, Born D, Putora P M. Treatment of limited disease small cell lung cancer: the multidisciplinary team. *European Respiratory Journal* 2017;.
- Ess S M, Herrmann C, Frick H, Krapf M, Cerny T, Jochum W, Früh M. Epidermal growth factor receptor and anaplastic lymphoma kinase testing and mutation prevalence in patients with advanced non-small cell lung cancer in Switzerland: A comprehensive evaluation of real world practices. *Eur J Cancer Care (Engl)* 2017;.
- Delaunay M, Cadranet J, Lusque A, Meyer N, Gounant V, Moro-Sibilot D, Michot J M, Raimbourg J, Girard N, Guisier F, Planchard D, Metivier A C, Tomasini P, Dansin E, Pérol M, Campana M, Gautschi O, Früh M, Fumet J D, Audigier-Valette C, Couraud S, Dalle S, Leccia M T, Jaffro M, Collot S, Prévot G, Milia J, Mazières J. Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients. *Eur Respir J* 2017; 50:.
- siano m, Molinari F, Martin V, Mach N, Früh M, Freguia S, Corradino I, Ghielmini M, Frattini M, Espeli V. Multicenter Phase II Study of Panitumumab in Platinum Pretreated, Advanced Head and Neck Squamous Cell Cancer. *Oncologist* 2017;.
- Diem S, Schmid S, Krapf M, Flatz L, Born D, Jochum W, Templeton A J, Früh M. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. *Lung Cancer* 2017; 111:176-181.
- Bickel A, Koneth I, Enzler-Tschudy A, Neuweiler J, Flatz L, Früh M. Pembrolizumab-associated minimal change disease in a patient with malignant pleural mesothelioma. *BMC Cancer* 2016; 16:656.
- Reichegger H, Jochum W, Förbs D, Hader C, Früh M. Rapid Intracranial Response to Osimertinib in a Patient with Epidermal Growth Factor Receptor T790M-Positive Adenocarcinoma of the Lung. *Oncol Res Treat* 2016; 39:461-3.
- Neumair P, Joos L, Warschkow R, Dutly A, Ess S, Hitz F, Früh M, Brutsche M, Baty F, Krähenbühl S, cerny t, Joerger M. Erlotinib has comparable clinical efficacy to chemotherapy in pretreated patients with advanced non-small cell lung cancer (NSCLC): A propensity-adjusted, outcomes research-based study. *Lung Cancer* 2016; 100:38-44.
- Gautschi O, Rothschild S I, Li Q, Matter-Walstra K, Zippelius A, Betticher D C, Früh M, Stahel R A, Cathomas R, Rauch D, Pless M, Peters S, Froesch P, Zander T, Schneider M, Biaggi C, Mach N, Ochsenbein A F, . Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial. *Clin Lung Cancer* 2016;.
- Schmid S, Gautschi O, Rothschild S, Mark M, Froesch P, Klingbiel D, Reichegger H, Jochum W, Diebold J, Früh M. Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs). *J Thorac Oncol* 2016;.
- Hasan Ali O, Diem S, Markert E, Jochum W, Kerl K, French L E, Speiser D E, Früh M, Flatz L. Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer. *Oncoimmunology* 2016; 5:e1231292.
- Putora P M, Szentesi K, Glatzer M, Rodriguez R, Müller J, Baty F, Früh M. SUVmax and Tumour Location in PET-CT Predict Oncogene Status in Lung Cancer. *Oncol Res Treat* 2016; 39:681-686.

- Baty F, Joerger M, Früh M, Brutsche M. 61PD 24h-blood profile gene expression biomarkers of the response to targeted therapy in advanced non-squamous non-small cell lung cancer (NSCLC). *J Thorac Oncol* 2016; 11:S81.
- Früh M, Ris H B, Xyrafas A, Peters S, Mirimanoff R O, Gautschi O, Pless M, Stupp R. Preoperative chemoradiotherapy with cisplatin and docetaxel for stage IIIB non-small-cell lung cancer: 10-year follow-up of the SAKK 16/01 trial. *Ann Oncol* 2016; 27:1971-3.
- Koeberle D, Betticher D C, von Moos R, Dietrich D, Brauchli P, Baertschi D, Matter K, Winterhalder R, Borner M, Anchisi S, Moosmann P, Kollar A, Saletti P, Roth A, Früh M, Kueng M, Popescu R A, Schacher S, Hess V, Herrmann R. Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06). *Ann Oncol* 2015; 26:709-14.
- Pless M, Stupp R, Ris H B, Stahel R A, Weder W, Thierstein S, Gerard M A, Xyrafas A, Früh M, Cathomas R, Zippelius A, Roth A, Bijelovic M, Ochsenbein A, Meier U R, Mamot C, Rauch D, Gautschi O, Betticher D C, Mirimanoff R O, Peters S, . Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial. *Lancet* 2015; 386:1049-56.
- Mazières J, Barlesi F, Filleron T, Besse B, Monnet I, Beau-Faller M, Peters S, Dansin E, Früh M, Pless M, Rosell R, Wislez M, Fournel P, Westeel V, Cappuzzo F, Cortot A, Moro-Sibilot D, Milia J, Gautschi O. Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort. *Ann Oncol* 2015; 27:281-6.
- Gautschi O, Milia J, Cabarrou B, Bluthgen M V, Besse B, Smit E F, Wolf J, Peters S, Früh M, Koeberle D, Oulkhovir Y, Schuler M, Curioni-Fontecedro A, Huret B, Kerjouan M, Michels S, Pall G, Rothschild S, Schmid-Bindert G, Scheffler M, Veillon R, Wannesson L, Diebold J, Zalcman G, Filleron T, Mazières J. Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort. *J Thorac Oncol* 2015; 10:1451-7.
- Gautschi O, Mach N, Rothschild S I, Li Q, Stahel R A, Zippelius A, Cathomas R, Früh M, Betticher D C, Peters S, Rauch D, Feilchenfeldt J, Bubendorf L, Savic S, Jaggi R, Leibundgut E O, Largiadèr C, Brutsche M, Pilop C, Stalder L, Pless M, Ochsenbein A F, Swiss Group for Clinical Cancer Research . Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09. *Clin Lung Cancer* 2015; 16:358-65.
- Putora P M, Ess S, Panje C, Hundsberger T, van Leyen K, Plasswilm L, Früh M. Prognostic significance of histology after resection of brain metastases and whole brain radiotherapy in non-small cell lung cancer (NSCLC). *Clin Exp Metastasis* 2015; 32:143-9.
- Stahel R A, Riesterer O, Xyrafas A, Opitz I, Beyeler M, Ochsenbein A, Früh M, Cathomas R, Nackaerts K, Peters S, Mamot C, Zippelius A, Mordasini C, Caspar C B, Eckhardt K, Schmid R A, Aebbersold D M, Gautschi O, Nagel W, Töpfer M, Krayenbuehl J, Ribi K, Ciernik L F, Weder W. Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial. *Lancet Oncol* 2015; 16:1651-8.
- Joerger M, Baty F, Früh M, Droege C, Stahel R A, Betticher D C, von Moos R, Ochsenbein A, Pless M, Gautschi O, Rothschild S, Brauchli P, Klingbiel D, Zappa F, Brutsche M. Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05). *Lung Cancer* 2014; 85:306-13.

- Leitner C, Von Moos R, Früh M, Mark M, Cathomas R. Progressive brain metastases in an EGFR mutated adenocarcinoma of the lung: Response to gefitinib after progression on erlotinib. *Cancer Treatment Communications* 2014; 2:4-7.
- Sebastian M, Papachristofilou A, Weiss C, Früh M, Cathomas R, Hilbe W, Wehler T, Rippin G, Koch S D, Scheel B, Fotin-Mleczek M, Heidenreich R, Kallen K J, Gnad-Vogt U, Zippelius A. Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNAActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer. *BMC Cancer* 2014; 14:748.
- Diem S, Ess S, cerny t, Früh M, Hitz F. Diffuse large B-cell lymphoma in elderly patients: a retrospective analysis. *Eur J Intern Med* 2014; 25:577-82.
- Schwitter M, Rodriguez R, Schneider T, Kluckert T, Brutsche M, Früh M. Epidermal growth factor receptor mutation in a patient with squamous cell carcinoma of the lung: who should be tested?. *Case Rep Oncol* 2013; 6:263-8.
- Baty F, Rothschild S, Früh M, Betticher D, Dröge C, Cathomas R, Rauch D, Gautschi O, Bubendorf L, Crowe S, Zappa F, Pless M, Brutsche M, Swiss Group for Clinical Cancer Research . EGFR Exon-Level Biomarkers of the Response to Bevacizumab/Erlotinib in Non-Small Cell Lung Cancer. *PLoS ONE* 2013; 8:e72966.
- Putora P M, Früh M, Müller J. FDG-PET SUV-max values do not correlate with epidermal growth factor receptor mutation status in lung adenocarcinoma. *Respirology* 2013; 18:734-5.
- Diem S, Früh M, Rodriguez R, Liechti P, Rothermundt C. EML4-ALK-Positive Pulmonary Adenocarcinoma with an Unusual Metastatic Pattern: A Case Report. *Case Rep Oncol* 2013; 6:316-9.
- Schwitter M, Früh M, Schneider T, Kluckert J T, Rodriguez R, Brutsche M. Epidermal Growth Factor Receptor Mutation in a Patient with Squamous Cell Carcinoma of the Lung: Who Should Be Tested?. *Oncology* 2013; 2013:263-268.
- Früh M, Besrou H, Gillessen Sommer S, Joerger M, Hitz F, Savidan A, cerny t, Ess S. Management of elderly patients with advanced non-small cell lung cancer: a single-center experience. *Chemotherapy* 2013; 59:42-50.
- Früh M, Cathomas R, siano m, Tscherry G, Zippelius A, Mamot C, Erdmann A, Krasniqi F, Rauch D, Simcock M, Küttel E, Fustier P, Pless M, Swiss Group for Clinical Cancer Research . Carboplatin and paclitaxel plus ASA404 as first-line chemotherapy for extensive-stage small-cell lung cancer: a multicenter single arm phase II trial (SAKK 15/08). *Clin Lung Cancer* 2012; 14:34-9.
- Rossi A, Di Maio M, Chiodini P, Rudd R, Okamoto H, Skarlos D, Früh M, Qian W, Tamura T, Samantas E, Shibata T, Perrone F, Gallo C, Gridelli C, Martelli O, Lee S. Carboplatin- or Cisplatin-based chemotherapy in first-line treatment of scmall cell lung cancer: The COCIS individual patient data meta-analysis. *J Clin Oncol* 2012;1692-1698.
- Joerger M, Matter-Walstra K, Früh M. Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost–utility analysis. *Ann Oncol* 2012; 22:567-574.
- Putora P M, Schneider T, Rodriguez R, Früh M. Targeted therapy in non-small cell lung cancer. *Breathe* 2012; 8:206-215.
- hochstrasser a, Benz G, Joerger M, templeton a, Brutsche M, Früh M. Interstitial Pneumonitis after Treatment with Pemetrexed: A Rare Event?. *Chemotherapy* 2012; 58:84-88.

- Joerger M, Matter-Walstra K, Früh M, Kühnel U, Szucs T, Pestalozzi B, Schwenkglenks M. Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis. *Ann Oncol* 2012; 22:567-574.
- Putora P M, Benz G, Rodriguez R, Brutsche M, Früh M. Tracheal granuloma pyogenicum with erlotinib treatment for lung cancer. *Eur Respir J* 2011; 38:1228-30.
- Früh M, Kacsir B, Ess S, cerny t, Rodriguez R, Plasswilm L. Extrapulmonary small cell carcinoma: An indication for prophylactic cranial irradiation? A single center experience. *Strahlenther Onkol* 2011; 187:561-7.
- bastian s, Clerici T, Neuweiler J, cerny t, Früh M. Surgical resection of isolated adrenal metastases in patients with non-small cell lung cancer: a single-institution experience and review of the literature. *Onkologie* 2011; 34:665-70.
- Putora P M, Früh M. The place of radiotherapy in the palliative management of NSCLC. *Breathe* 2011; 8: 134-143 2011;.
- Stahel R, Thatcher N, Früh M, Le Péchoux C, Postmus P E, Sorensen J B, Felix E, Panel members . 1st ESMO Consensus Conference in lung cancer; Lugano 2010: small-cell lung cancer. *Ann Oncol.* 2011; 22:1973-1980.
- Früh M. The search for improved systemic therapy of non-small cell lung cancer--what are today's options?. *Lung Cancer* 2011; 72:265-270.
- D'Addario G, Früh M, Reck M, Baumann P, Klepetko W, Felip E, ESMO Guidelines Working Group . Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2010; 21 Suppl 5:v116-9.
- Joerger M, Matter-Walstra K, Früh M, Kühnel U, Szucs T, Pestalozzi B, Schwenkglenks M. Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis. *Ann Oncol* 2010; 22:567-74.
- Joerger M, Omlin A, cerny t, Früh M. The role of pemetrexed in advanced non small-cell lung cancer: special focus on pharmacology and mechanism of action. *Current drug targets* 2010; 11:37-47.
- Früh M, Shepherd F. Adjuvant Cisplatin-Based Chemotherapy for Elderly. *EUROPEAN JOURNAL OF CLINICAL & MEDICAL ONCOLOGY* 2010;59-63.
- Omlin A, D'Addario G, Gillessen Sommer S, cerny t, vonhessling a, Früh M. Activity of pemetrexed against brain metastases in a patient with adenocarcinoma of the lung. *Lung cancer (Amsterdam, Netherlands)* 2009; 65:383-4.
- Früh M, Pignon J P, Shepherd F. Review Article: Elderly patients with early non-small cell lung cancer: What are the benefits and harms of adjuvant platinum-based chemotherapy?. *AJHO* 2009; 8:76-79.
- Cerny D, cerny t, ess s, D'Addario G, Früh M. Lung Cancer in the Canton of St. Gallen, Eastern Switzerland:. *Onkologie* 2009; 32:569-73.
- Früh M, Rolland E, Pignon J P, Seymour L, Ding K, Tribodet H, Winton T, Le Chevalier T, Scagliotti G V, Douillard J Y, Spiro S, Shepherd F A. Pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small-cell lung cancer. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2008; 26:3573-81.
- Früh M, Gillessen Sommer S, cerny t, Demmer-Steingruber R, D'Addario G. Two-weekly gemcitabine fixed dose rate and oxaliplatin combination chemotherapy for advanced non-small-cell lung cancer. *Lung cancer (Amsterdam, Netherlands)* 2008; 62:344-50.

- Früh M, Zhou W, Zhai R, Su L, Heist R S, Wain J C, Nishioka N S, Lynch T J, Shepherd F A, Christiani D C, Liu G. Polymorphisms of inflammatory and metalloproteinase genes, *Helicobacter pylori* infection and the risk of oesophageal adenocarcinoma. *British journal of cancer* 2008; 98:689-92.
- Lanz C, Früh M, Thormann W, cerny t, Lauterburg B H. Rapid determination of gemcitabine in plasma and serum using reversed-phase HPLC. *Journal of separation science* 2007; 30:1811-20.
- Rodin G, Zimmermann C, Rydall A, Jones J, Shepherd F A, Moore M, Früh M, Donner A, Gagliese L. The desire for hastened death in patients with metastatic cancer. *Journal of pain and symptom management* 2007; 33:661-75.
- Früh M, Ruhstaller T, Neuweiler J, cerny t. Resection of skin metastases from gastric carcinoma with long-term follow-up: an unusual clinical presentation. *Onkologie* 2005; 28:38-40.
- Früh M. Use of second-line biochemical and susceptibility tests for the differential identification of coryneform bacteria. *Clinical Microbiology and Infection* 1998; Vol. 4 June 1998:.

## book chapter

- Früh M (2014). Advances in Radiotherapy for Locally Advanced NSCLC. In *New Therapeutic Strategies in Lung Cancers* (pp. 69-94): Springer.
- Früh M (2014). Strategy on Patients with EGFR Mutation. In *New Therapeutic Strategies in Lung Cancers* (pp. 133-145): Springer.
- Früh M, Baty F, Putora P M, & Brutsche M (2011). Advances in Personalized Cancer Management. In *Advances in Personalized Cancer Management* (pp. 58-67). London: Future Medicine Ltd.

## conference paper/poster

- Neumair P, Joos L, Warschkow R, Ess S, Hitz F, Früh M, Brutsche M, Baty F, Krähenbühl S, & Joerger M (2016). Chemotherapy is not superior to erlotinib in pretreated patients with advanced non-small cell lung cancer (NSCLC): A retrospective study: Abstrakt 169P. In *J Thorac Oncol.* 11(4 Suppl) (pp. 131): Elsevier.
- Klass N, Klaeser B, toepfer m, Malthaner M, Früh M, Schmidhalter D, Cihoric N, Born E, Blumstein N, Plasswilm L, Krause T, Aebersold D, & Schmuecking M (2012). Non-Gated F-18 FDG PET/CT For Target Volume Delineation in Stereotactic Body Radiation Therapy (SBRT) in Patients with Malignant Lung Lesions and Clinical Outcome. In (pp. 106): SASRO.